- US-listed companies
- Ovid Therapeutics Inc.
- Income statement
Ovid Therapeutics Inc.OVID
Market cap
$105.24M
P/E ratio
| 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | 13 | 221 | 223 | 223 | 1 |
| Revenue growth (%) | - | - | - | - | ||||
| Research & development | 50 | 34 | 42 | 63 | 47 | 25 | 29 | 37 |
| Operating margin (%) | - | - | - | |||||
| Operating income | -65,007,563 | -52,931,683 | -61,409,467 | -81,430,977 | 124 | -55,548,161 | -59,281,464 | -62 |
| Operating expenses | 65 | 53 | 61 | 94 | 84 | 57 | 60 | 62 |
| Income before tax | - | - | - | - | 124 | -54,169,029 | -52,338,959 | -26 |
| Pretax margin (%) | - | - | - | - | 56.2 | -24.3 | -23.5 | -4,670.1 |
| Provision for income taxes | - | - | - | - | 1 | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | |
| Net income | -64,806,054 | -51,979,610 | -60,461,243 | -81,035,576 | 123 | -54,169,029 | -52,338,959 | -26 |
| Net income margin (%) | - | - | - | |||||
| Earnings per share | - | - | - | - | 1.78 | -0.77 | -0.74 | - |
| Diluted EPS | - | - | - | - | 1.76 | -0.77 | -0.74 | - |
| EBITDA | ||||||||
| EBITDA margin (%) | - | - | - |